Inflammatory parameters in NSCLC with driver mutation

Figures & data

Table 1. Presents the sociodemographic and clinic characteristics.

	n	%
Age – <65 years – ≥65 years	24 14	(63.2) (36.8)
Sex – Women – Men	17 21	(44.7) (55.3)
ECOG – 0 – 1 – 2 – 3	3 23 10 2	(7.9) (60.5) (26.3) (5.3)
Smoking status – No – Yes	24 13	(63.2 (34.2)
Comorbidity – No – Yes	26 10	(68.4) (26.3)
Mutation – EGFR – ALK – ROS – BRAF	23 12 2 1	(60.5) (31.6) (5.3) (2.6)
Which series – First line – Second line and after	19 19	(50.0) (50.0)
Metastasis site in diagnosis – Lung – Brain – Bone – Surrenal – Multiple	13 7 12 3 2	(34.2) (18.4) (31.6) (7.9) (5.3)
Brain metastases on follow-up – No – Yes	8 29	(21.1) (76.3)
Progression – No – Yes	6 32	(15.8) (84.2)
Latest status – Live – Exitus	8 30	(21.1) (78.9)
NLR – <2.57 – ≥2.57	13 25	(34.2) (65.8)
PNI – <37.7 – ≥37.7	21 17	(55.3) (44.7)
SII – <799.5 – ≥799.5	14 24	(36.8) (63.2)
Neutrophil – <5.2 – ≥5.2	15 23	(39.5) (60.5)
Lymphocyte – <2.03 – ≥2.03	21 17	(55.3) (44.7)

ECOG: Eastern Cooperative Oncology Group; NLR: Neutrophil–lymphocyte ratio; PNI: Prognostic nutritional index; SII: Systemic immune-inflammation index.

Table 2. The relationship between inflammatory indices and other variables.

	NLR			PNI			SII
	<2.57	≥2.57	p-value	<37.7	≥37.7	p-value	<799.5	≥799.5	p-value
Age – <65 years – ≥65 years	12 (92.3) 1 (7.7)	12 (48.0) 13 (52.0)	0.012	13 (61.9) 8 (38.1)	11 (64.7) 6 (35.3)	0.859	11 (78.6) 3 (21.4)	13 (54.2) 11 (45.8)	0.132
Sex – Women – Men	11 (84.6) 2 (15.4)	10 (40.0) 15 (60.0)	0.009	14 (66.7) 7 (33.3)	7 (41.2) 10 (58.8)	0.116	11 (78.6) 3 (21.4)	10 (41.7) 14 (58.3)	0.027
ECOG – 0 – 1 – 2 – 3	1 (7.7) 8 (61.5) 4 (30.8) 0 (0.0)	2 (8.0) 15 (60.0) 6 (24.0) 2 (8.0)	0.935	1 (4.8) 11 (52.4) 7 (33.3) 2 (9.5)	2 (11.8) 12 (70.6) 3 (17.6) 0 (0.0)	0.387	1 (7.1) 9 (64.3) 4 (28.6) 0 (0.0)	2 (8.3) 14 (58.3) 6 (25.0) 2 (8.3)	0.875
Smoking – No – Yes	11 (84.6) 2 (15.4)	13 (54.2) 11 (45.8)	0.083	14 (70.0) 6 (30.0)	10 (58.8) 7 (41.2)	0.478	12 (85.7) 2 (14.3)	12 (52.2) 11 (47.8)	0.074
Comorbidity – No – Yes	9 (69.2) 4 (30.8)	17 (73.9) 6 (26.1)	1.000	14 (70.0) 6 (30.0)	12 (75.0) 4 (25.0)	>0.999	10 (76.9) 3 (23.1)	16 (69.6) 7 (30.4)	0.716
Mutation – EGFR – ALK – ROS – BRAF	4 (30.8) 7 (53.8) 2 (15.4) 0 (0.0)	19 (76.0) 5 (20.0) 0 (0.0) 1 (4.0)	0.005	11 (52.4) 9 (42.9) 0 (0.0) 1 (4.8)	12 (70.6) 3 (17.6) 2 (11.8) 0 (0.0)	0.099	5 (35.7) 7 (50.0) 2 (14.3) 0 (0.0)	18 (75.0) 5 (20.8) 0 (0.0) 1 (4.2)	0.015
Which series – First line – Seond line and after	8 (61.5) 5 (38.5)	11 (44.0) 14 (56.0)	0.305	12 (57.1) 9 (42.9)	7 (41.2) 10 (58.8)	0.328	9 (64.3) 5 (35.7)	10 (41.7) 14 (58.3)	0.179
Metastasis site in diagnosis – Lung – Brain – Bone – Surrenal – Multiple	10 (76.9) 1 (7.7) 2 (15.4) 0 (0.0) 0 (0.0)	3 (12.5) 6 (25.0) 10 (41.7) 3 (12.5) 2 (8.3)	0.002	8 (40.0) 5 (25.0) 2 (10.0) 3 (15.0) 2 (10.0)	5 (29.4) 2 (11.8) 10 (58.8) 0 (0.0) 0 (0.0)	0.011	10 (71.4) 1 (7.1) 3 (21.4) 0 (0.0) 0 (0.0)	3 (13.0) 6 (26.1) 9 (39.1) 3 (13.0) 2 (8.7)	0.006
Brain metastases on follow-up – No – Yes	11 (84.6) 2 (15.4)	18 (75.0) 6 (25.0)	0.685	17 (81.0) 4 (19.0)	12 (75.0) 4 (25.0)	0.705	11 (78.6) 3 (21.4)	18 (78.3) 5 (21.7)	1.000
Progression – No – Yes	4 (30.8) 9 (69.2)	2 (8.0) 23 (92.0)	0.154	2 (9.5) 19 (90.5)	4 (23.5) 13 (76.5)	0.378	5 (35.7) 9 (64.3)	1 (4.2) 23 (95.8)	0.018
Latest status – Live – Exitus	5 (38.5) 8 (61.5)	3 (12.0) 22 (88.0)	0.094	3 (14.3) 18 (85.7)	5 (29.4) 12 (70.6)	0.426	5 (35.7) 9 (64.3)	3 (12.5) 21 (87.5)	0.117

Bold p-values indicate they are statistically significant.

ECOG: Eastern Cooperative Oncology Group; NLR: Neutrophil–lymphocyte ratio; PNI: Prognostic nutritional index; SII: Systemic immune-inflammation index.

Figure 1. Progression-free survival relationship of age and inflammatory parameters, Kaplan-Meier graphics.

(A) Age, (B) NLR, (C) SII and (D) lymphocyte. NLR: Neutrophil–lymphocyte ratio; PFS: Progression-free survival; SII: Systemic immune inflammation index.

Figure 2. Overall survival relationship of age and inflammatory parameters, Kaplan-Meier graphics.

(A) Age, (B) NLR, (C) SII and (D) lymphocyte. NLR: Neutrophil–lymphocyte ratio; OS: Overall survival; SII: Systemic immune inflammation index.

Table 3. Progression-free survival and overall survival relationships with categorical data.

	PFS			OS
	Mean	Median	p-value	Mean	Median	p-value
Age – <65 years – ≥65 years	36.2 15.8	21.7 13.3	0.006	46.4 22.5	58.3 14.4	0.002
Sex – Women – Men	31.6 25.7	18.0 16.6	0.332	39.1 33.5	31.7 21.7	0.540
ECOG – 1 – 2	31.3 25.5	17.9 17.6	0.763	35.3 37.7	21.7 23.4	0.592
Smoking – No – Yes	34.9 20.4	22.4 14.0	0.036	40.0 31.5	31.7 21.7	0.463
Comorbidity – No – Yes	29.6 27.9	17.9 12.1	0.707	38.6 31.5	27.1 21.6	0.563
Mutation – EGFR – ALK	21.1 39.0	13.3 25.9	0.371	27.4 48.5	18.0 46.4	0.211
Which series – First line – Second line and after	32.3 24.4	18.0 17.5	0.478	40.1 33.1	46.4 23.0	0.580
Metastasis site in diagnosis – Lung – Brain – Bone	44.2 19.1 25.3	48.8 17.5 13.4	0.083	51.4 33.2 27.9	59.6 27.1 19.3	0.136
Brain metastases on follow-up – No – Yes	31.8 21.6	21.7 13.4	0.117	37.8 33.8	27.1 19.4	0.688
NLR – <2.57 – ≥2.57	46.2 19.9	48.8 13.4	0.002	51.8 28.5	59.5 19.3	0.013
PNI – <37.7 – ≥37.7	23.3 34.5	17.5 31.4	0.216	33.2 40.2	21.7 40.1	0.500
SII – <799.5 – ≥799.5	45.6 20.1	48.8 13.4	0.003	48.3 29.5	59.5 19.4	0.042
Neutrophil – <5.2 – ≥5.2	40.7 21.3	23.0 14.5	0.024	46.4 30.1	37.5 21.6	0.078
Lymphocyte – <2.03 – ≥2.03	17.6 43.1	13.3 48.8	0.001	27.0 47.8	18 49.9	0.025

Bold p-values indicate they are statistically significant.

ECOG: Eastern Cooperative Oncology Group; NLR: Neutrophil–lymphocyte ratio; OS: Overall survival; PFS: Progression-free survival; PNI: Prognostic nutritional index; SII: Systemic immune-inflammation index.